Clinical Therapeutics

Finerenone-Based Dual Versus Triple Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Mellitus Associated Chronic Kidney Disease: A Retrospective Cohort Study

By Mohammed Khogalee, Sami Mohamed, Michael Ekubu Otim, Ali El Houni

Figure 1 from Clinical Therapeutics — Figure 1. Khogalee et al.

Cohort study of 83 peopleInterventions

6 months, multicentre, declared no competing interests

The paper

Mohammed Khogalee, Sami Mohamed, Michael Ekubu Otim, Ali El Houni

Queen Elizabeth the Queen Mother Hospital; College of Medicine

Clinical Therapeutics, 8 Sep 2026

doi.org/10.1016/j.clinthera.2026.08.004 PubMed 42711176

Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk